No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
www.hspharm.comNo one on the platform currently holds 3692.HK.
No tracked institution reports a position in 3692.HK as of their last filing.
No one on the platform has traded 3692.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 14.3% | 30.7% | 125.2% | — | — | — |
| Rev. Growth % | 22.6% | 11.6% | ||||
| Profit Margin % | 37.0% | 32.0% | 29.7% | |||
| Free Cash Flow Margin % | 41.6% | 29.5% | 24.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $17.8B | +20.2% | $1.12 | $1.00–$1.25 | — | 20 |
| 2027 | $19.5B | +9.6% | $1.19 | $0.93–$1.33 | — | 20 |
| 2028 | $22.1B | +13.3% | $1.34 | $1.19–$1.54 | — | 18 |
| 2029 | $28.6B | +29.1% | $1.74 | $1.63–$2.01 | — | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.56 | $0.81 | +43.0% |
| 2026-03-29 | $0.38 | $0.45 | +17.7% |
| 2025-08-18 | $0.39 | $0.58 | +47.1% |
| 2025-03-24 | $0.24 | $0.30 | +21.7% |
| 2024-08-27 | $0.42 | $0.49 | +18.0% |
| 2024-03-26 | $0.24 | $0.36 | +49.2% |
| 2023-08-31 | $0.25 | $0.23 | -5.7% |
| 2023-03-27 | $0.24 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 3692.HKHansoh Pharmaceutical Group Company Limited | $33.92 | -1.40% | $205.7B | — |
| 0512.HKGrand Pharmaceutical Group Limited | $4.89 | +0.31% | $17.1B | — |
| 0867.HKChina Medical System Holdings Limited | $10.90 | -2.07% | $26.5B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $13.19 | -0.75% | $32.8B | — |
| 1177.HKSino Biopharmaceutical Limited |
| $0.25 |
| +2.8% |
| $5.42 |
| -0.91% |
| $96.6B |
| — |
| 1801.HKInnovent Biologics, Inc. | $94.65 | -2.27% | $164.8B | — |
| 2196.HKShanghai Fosun Pharmaceutical (Group) Co., Ltd. | $16.89 | -1.34% | $63.3B | — |
Source: Financial Modeling Prep · peers by sector/industry